CN112904008B - 检测生物制品中蛋白a等杂质的酶联免疫试剂盒及其应用 - Google Patents
检测生物制品中蛋白a等杂质的酶联免疫试剂盒及其应用 Download PDFInfo
- Publication number
- CN112904008B CN112904008B CN202110118057.1A CN202110118057A CN112904008B CN 112904008 B CN112904008 B CN 112904008B CN 202110118057 A CN202110118057 A CN 202110118057A CN 112904008 B CN112904008 B CN 112904008B
- Authority
- CN
- China
- Prior art keywords
- gentamicin
- solution
- protein
- antibody
- enzyme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 41
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 41
- 238000008157 ELISA kit Methods 0.000 title claims abstract description 13
- 239000012535 impurity Substances 0.000 title claims abstract description 10
- 229960002518 gentamicin Drugs 0.000 claims abstract description 60
- 229930182566 Gentamicin Natural products 0.000 claims abstract description 55
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 claims abstract description 55
- 239000000243 solution Substances 0.000 claims abstract description 44
- 102000004190 Enzymes Human genes 0.000 claims abstract description 24
- 108090000790 Enzymes Proteins 0.000 claims abstract description 24
- 239000000427 antigen Substances 0.000 claims abstract description 21
- 102000036639 antigens Human genes 0.000 claims abstract description 21
- 108091007433 antigens Proteins 0.000 claims abstract description 21
- 239000011248 coating agent Substances 0.000 claims abstract description 17
- 238000000576 coating method Methods 0.000 claims abstract description 17
- 238000002965 ELISA Methods 0.000 claims abstract description 15
- 230000002163 immunogen Effects 0.000 claims abstract description 14
- 238000005406 washing Methods 0.000 claims abstract description 13
- 239000000758 substrate Substances 0.000 claims abstract description 12
- 238000010168 coupling process Methods 0.000 claims abstract description 10
- 238000005859 coupling reaction Methods 0.000 claims abstract description 10
- 230000008878 coupling Effects 0.000 claims abstract description 9
- 239000012086 standard solution Substances 0.000 claims abstract description 8
- 239000012089 stop solution Substances 0.000 claims abstract description 8
- 230000003053 immunization Effects 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims abstract description 4
- 239000003085 diluting agent Substances 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 11
- 239000007853 buffer solution Substances 0.000 claims description 10
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 229940098773 bovine serum albumin Drugs 0.000 claims description 6
- 238000004090 dissolution Methods 0.000 claims description 6
- 108010058846 Ovalbumin Proteins 0.000 claims description 5
- 229940092253 ovalbumin Drugs 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000006243 chemical reaction Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- KHAWDEWNXJIVCJ-UHFFFAOYSA-N 1-fluoro-4-(4-fluoro-3-nitrophenyl)sulfonyl-2-nitrobenzene Chemical compound C1=C(F)C([N+](=O)[O-])=CC(S(=O)(=O)C=2C=C(C(F)=CC=2)[N+]([O-])=O)=C1 KHAWDEWNXJIVCJ-UHFFFAOYSA-N 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 2
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims description 2
- 239000012074 organic phase Substances 0.000 claims description 2
- 239000012071 phase Substances 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 abstract description 3
- 230000035945 sensitivity Effects 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 26
- 239000007788 liquid Substances 0.000 description 14
- 238000001514 detection method Methods 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 6
- 238000007789 sealing Methods 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000010009 beating Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 108010017384 Blood Proteins Proteins 0.000 description 3
- 102000004506 Blood Proteins Human genes 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical group C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 108091006020 Fc-tagged proteins Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940078916 carbamide peroxide Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000007865 diluting Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 2
- GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical group NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- ASXBYYWOLISCLQ-UHFFFAOYSA-N Dihydrostreptomycin Natural products O1C(CO)C(O)C(O)C(NC)C1OC1C(CO)(O)C(C)OC1OC1C(N=C(N)N)C(O)C(N=C(N)N)C(O)C1O ASXBYYWOLISCLQ-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000003452 antibody preparation method Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 125000005587 carbonate group Chemical group 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 229960002222 dihydrostreptomycin Drugs 0.000 description 1
- ASXBYYWOLISCLQ-HZYVHMACSA-N dihydrostreptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](CO)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O ASXBYYWOLISCLQ-HZYVHMACSA-N 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 238000011143 downstream manufacturing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9446—Antibacterials
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
- G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明提供了一种检测生物制品中蛋白A等杂质的酶联免疫试剂盒,它包括:包被有包被原的酶标板、蛋白A标准品溶液、庆大霉素标准品溶液、蛋白A抗体、庆大霉素抗体、酶结合物浓缩液、酶结合物稀释液、底物显色液、终止液、洗涤液,所述包被原为庆大霉素偶联抗原,所述酶结合物为酶标记的蛋白A抗体、酶标记的庆大霉素抗体,所述蛋白A抗体和庆大霉素抗体均是由免疫原免疫动物得到的。本发明提供的酶联免疫试剂盒可用于检测生物制品中蛋白A等杂质含量,其操作简便、费用低廉、灵敏度高、能够现场监控且适合大量样本的筛查。
Description
技术领域
本发明涉及检测生物制品中蛋白A等杂质的酶联免疫试剂盒及其应用,具体涉及一种蛋白A免疫方法和庆大霉素人工抗原分子结构以及用于检测蛋白A的酶联免疫试剂盒,用于测定生物制品中该类杂质的残留量。
背景技术
WHO、ICH的相关法规及中国药典2010年版三部均对杂质的去除及残留限度有描述和规定。蛋白A(Protein A,ProA)是最早发现的与免疫球蛋白结合的分子之一,其作为亲和色谱的重要介质,广泛应用于Fc融合蛋白和单克隆抗体的纯化工艺过程中,ProA亲和色谱法用于纯化,优点是高性能和高纯度,缺点是能浸出ProA,属于下游工艺源杂质。浸出的ProA一方面作为金黄色葡萄球菌的膜蛋白具有免疫原性,有促有丝分裂的作用,所以控制其残留水平是保证药物安全性的一项重要指标,另外,残留ProA检测在工艺过程中也是监测色谱柱完整性的工具。残留ProA检测中,因ProA具有能够结合IgG分子的特点,从而阻碍其与相应抗体的结合,常常造成检测结果的不准确,所以该项目不但是重组Fc融合蛋白和单克隆抗体质量控制的重要指标,也一直是质量控制的难点。另外,庆大霉素等抗生素也可能存在于生物制品中,是需要检测的杂质。
通过免疫化学检测法对药物进行检测,具有快速、特异、灵敏、准确、可以批量监测、样品处理简单、能实现自动化操作等优点。本申请研究出蛋白A和庆大霉素的抗体制备方法,以便应用于快速检测方法。
发明内容
本发明的目的在于提供一种抗体制备技术,具体涉及一种用于检测蛋白A和庆大霉素的抗体制备方法,制备出的抗体可应用于快速检测方法,比如酶联免疫试剂盒。
本发明的酶联免疫试剂盒,它包括:包被有包被原的酶标板、标准品溶液、抗体、酶结合物浓缩液、酶结合物稀释液、底物显色液、终止液、洗涤液,所述包被原分别为庆大霉素偶联抗原、蛋白A,所述酶结合物分别为酶标记的庆大霉素抗体、蛋白A抗体。
所述庆大霉素偶联抗原是由庆大霉素半抗原与载体蛋白偶联得到,所述庆大霉素半抗原是由庆大霉素与4,4′-二氟-3,3′-二硝基二苯砜等物质经过一系列化学反应得到,所述载体蛋白为鼠血清蛋白、甲状腺蛋白、猪尿白蛋白、兔血清蛋白、人血清蛋白、卵清蛋白、血蓝蛋白或纤维蛋白原。
所述庆大霉素抗体是以庆大霉素偶联抗原作为免疫原制备获得,所述庆大霉素特异性抗体可为庆大霉素单克隆抗体或庆大霉素多克隆抗体,其中优选庆大霉素单克隆抗体。
所述蛋白A抗体是以蛋白A作为免疫原制备获得,所述蛋白A抗体可为蛋白A单克隆抗体或蛋白A多克隆抗体,其中优选蛋白A单克隆抗体。
所述酶结合物的标记酶为辣根过氧化物酶或细菌提取碱性磷酸酯酶,其中优选辣根过氧化物酶;酶结合物是由酶和抗体偶联得到的。
为了更方便现场监控和大量样本筛查,所述试剂盒还包括标准品溶液、底物显色液、终止液、洗涤液。
所述庆大霉素标准品溶液6瓶,浓度分别为0μg/L,0.1μg/L,0.3μg/L,0.9μg/L,2.7μg/L,8.1μg/L。
所述蛋白A标准品溶液6瓶,浓度分别为0mg/L,0.2mg/L,0.6mg/L,1.8mg/L,5.4mg/L,16.2mg/L。
当标记酶为辣根过氧化物酶时,所述底物显色液由底物液A液和底物液B液组成,A为过氧化氢或过氧化脲,B液为邻苯二胺或四甲基联苯胺,所述终止液为1~2mol/L的硫酸溶液或盐酸缓冲液;当标记酶为细菌提取碱性磷酸酯酶时,所述底物显色液为对硝基磷酸盐缓冲液,所述终止液为1~2mol/L氢氧化钠溶液。
所述洗涤液优选为pH值为7.4,含有0.5%~1.0%吐温-20、0.01‰~0.03‰叠氮化钠防腐剂、0.1~0.3mol/L的磷酸盐缓冲液,所述百分比为重量体积百分比。
其中在酶标板制备过程中所用到的包被缓冲液为pH值为9.6,0.05mol/L的碳酸盐缓冲液,封闭液为pH值为7.1~7.5,含有1%~3%酪蛋白、0.1~0.3mol/L的磷酸盐缓冲液,所述百分比为重量体积百分比。
本发明中酶标板的制备过程为:用包被缓冲液将包被原稀释成20μg/mL,每孔加入50μl-100μl,25℃避光孵育2h或4℃过夜,倾去孔中液体,用洗涤液洗涤2次,每次30s,拍干,然后在每孔中加入150~200μl封闭液,25℃避光孵育1~2h,倾去孔内液体拍干,干燥后用铝膜真空密封保存。
本发明的检测原理为:
蛋白A试剂盒采用直接竞争ELISA方法,在酶标板微孔条上预包被免疫原,样本中残留的蛋白A和酶标板微孔条上预包被的免疫原竞争抗蛋白A的酶结合物,用TMB底物显色,样本吸光度值与其所含残留物蛋白A的含量成负相关,与标准曲线比较,再乘以其对应的稀释倍数,即可得出样本中蛋白A的残留量。
庆大霉素试剂盒采用间接竞争ELISA方法,在酶标板微孔条上预包被偶联抗原,样本中残留的庆大霉素和酶标板微孔条上预包被的偶联抗原竞争抗庆大霉素的抗体,加入酶标二抗后,用TMB底物显色,样本吸光度值与其所含残留物庆大霉素的含量成负相关,与标准曲线比较,再乘以其对应的稀释倍数,即可得出样本中庆大霉素的残留量。
本发明的酶联免疫试剂盒主要采用ELISA方法定性或定量检测样品中待测物的含量;对样品的前处理要求低,样品前处理过程简单,能同时快速检测大批量样品;主要试剂以工作液的形式提供,检验方法方便易行,具有特异性高、灵敏度高、精确度高、准确度高等特点。本发明的酶联免疫试剂盒,结构简单、使用方便、价格便宜、携带便利、检测方法高效、准确、简便、适于大批量样品筛选的定性、定量。
附图说明
图1:庆大霉素半抗原合成路线图
具体实施方式
下面结合具体的实施例来进一步阐述本发明。应理解,这些实施例仅用于说明本发明,而不用来限制本发明的范围。
实施例1 试剂盒组分的制备
1、庆大霉素半抗原的制备
取庆大霉素1.39g,加纯水80ml溶解,取4,4′-二氟-3,3′-二硝基二苯砜0.344g加30ml甲醇溶解,加入到庆大霉素的水溶液中,加无水碳酸钾1.38g,室温搅拌3h,停止反应,加乙酸乙酯300ml萃取,静置,分去水相,有机相浓缩蒸干,无水乙醇20ml重结晶,得到氟硝基苯-庆大霉素半抗原产物0.34g,收率43.9%。
2、抗原的制备
免疫原制备——庆大霉素半抗原与牛血请白蛋白(BSA)偶联得到免疫原。
取氟硝基苯-庆大霉素半抗原产物29mg,加DMF2ml溶解,得到半抗原溶液A液;取牛血清白蛋白(BSA)50mg,加0.05M PB缓冲液溶解,得到B液,将A液滴加到B液中,4℃反应12h,0.02M PBS透析纯化3天,每天换液三次,得到庆大霉素-BSA偶联物,即为免疫原,-20℃保存,备用。
包被原制备——庆大霉素半抗原与卵清蛋白(OVA)偶联得到免疫原。
取氟硝基苯-庆大霉素半抗原产物16mg,加DMF1ml溶解,得到半抗原溶液A液;;取卵血清白蛋白(OVA)50mg,加0.05M PB缓冲液溶解,得到B液,将A液滴加到B液中,4℃反应12h,0.02M PBS透析纯化3天,每天换液三次,得到庆大霉素-OVA偶联物,即为包被原,-20℃保存,备用。
3、庆大霉素单克隆抗体和蛋白A单克隆抗体的制备
动物免疫:将庆大霉素免疫原/蛋白A注入到不同Balb/c小鼠体内,免疫剂量为150μg/只,使其产生抗血清。
细胞融合和克隆化:小鼠血清测定结果较高后,取其脾细胞,按8∶1(数量配比)比例与SP2/0骨髓瘤细胞融合,采用间接竞争ELISA测定细胞上清液,筛选阳性孔。利用有限稀释法对阳性孔进行克隆化,直到得到分泌庆大霉素单克隆抗体/蛋白A单克隆抗体的杂交瘤细胞株。
细胞冻存和复苏:将单克隆杂交瘤细胞株用冻存液制成1×106个/mL的细胞悬液,在液氮中长期保存。复苏时取出冻存管,立即放入37℃水浴中速融,离心去除冻存液后,移入培养瓶内培养。
单克隆抗体的生产与纯化:将Balb/c小鼠腹腔注入灭菌石蜡油0.5mL/只,7天后腹腔注射稳定的单克隆杂交瘤细胞株5×105个/只,7天后采集腹水。用辛酸-饱和硫酸铵法进行腹水纯化,-20℃保存。
4、酶结合物的制备
以山羊作为免疫动物,以单克隆抗体为免疫原对无病原体山羊进行免疫,得到相应抗体。将抗体与辣根过氧化物酶(HRP)进行偶联得到酶结合物。
5、酶标板的制备
用包被缓冲液将包被原稀释成20μg/mL,每孔加入100μl,25℃避光孵育2h,倾去孔中液体,用洗涤液洗涤2次,每次30s,拍干,然后在每孔中加入200μl封闭液,25℃避光孵育2h,倾去孔内液体拍干,干燥后用铝膜真空密封保存。
实施例2 酶联免疫试剂盒的组建
组建检测庆大霉素/蛋白A的酶联免疫试剂盒,使其包含下述组分:
(1)包被有包被原的酶标板;
(2)庆大霉素标准品溶液6瓶,浓度分别为0μg/L,0.1μg/L,0.3μg/L,0.9μg/L,2.7μg/L,8.1μg/L;蛋白A标准品溶液6瓶,浓度分别为0mg/L,0.2mg/L,0.6mg/L,1.8mg/L,5.4mg/L,16.2mg/L;
(3)用辣根过氧化物酶标记的抗体;
(4)底物显色液由A液和B液组成,A液为过氧化脲,B液为四甲基联苯胺;
(5)终止液为2mol/L硫酸;
(6)洗涤液为pH值为7.4,含有0.5%~1.0%吐温-20、0.01‰~0.03‰叠氮化钠防腐剂、0.1~0.3mol/L的磷酸盐缓冲液,所述百分比为重量体积百分比;
实施例3 生物制品中待测物的检测
1、用试剂盒检测
将样本和标准品对应微孔按序编号,每个样本和标准品做2孔平行,并记录标准孔和样本孔所在的位置。加入标准品/样本每孔20μl-80μl到对应的微孔中,然后加入酶结合物工作液每孔20μl-80μl,轻轻振荡混匀,用盖板膜盖板后置25℃避光环境中反应30min。将孔内液体甩干,加入洗涤工作液250μl/孔,充分洗涤4-5次,每次间隔10s,泼掉板孔内洗涤液,用吸水纸拍干。加入底物液A液50μl/孔,再加入底物液B液50μl/孔,轻轻振荡混匀,用盖板膜盖板后置25℃避光环境中反应15min。加入终止液50μl/孔,轻轻振荡混匀,设定酶标仪于450nm处,测定每孔OD值。
2、检测结果分析
标准品或样本的百分吸光率等于标准品或样本的吸光度值的平均值(双孔)除以第一个标准品(0标准)的吸光度值的平均值,再乘以100%,得到标准品或样本的百分吸光度值。以标准品百分吸光率为纵坐标,以标准品浓度(μg/L)的对数为横坐标,绘制标准曲线图。将样本的百分吸光率代入标准曲线中,从标准曲线上读出样本所对应的浓度,乘以其对应的稀释倍数即为样本中待测物的实际浓度。
实施例4 庆大霉素试剂盒的关键技术参数
1、试剂盒线性范围
试剂盒的线性范围为0.1~8.1μg/L。
2、试剂盒准确度
试剂盒的准确度为75%-95%。
3、试剂盒精密度
试剂盒的精密度:板内、板间变异系数均小于10%。
4、试剂盒特异性
庆大霉素约等于100%。
链霉素小于1%;
双氢链霉素小于1%;
新霉素小于1%。
实施例5 蛋白A试剂盒的关键技术参数
1、试剂盒线性范围
试剂盒的线性范围为0.2~16.2mg/L。
2、试剂盒准确度
试剂盒的准确度为70%-130%。
3、试剂盒精密度
试剂盒的精密度:板内、板间变异系数均小于10%。
Claims (3)
1.一种检测生物制品中蛋白A或庆大霉素杂质的酶联免疫试剂盒,其特征在于包括:包被有包被原的酶标板、蛋白A标准品溶液、庆大霉素标准品溶液、蛋白A抗体、庆大霉素抗体、酶结合物浓缩液、酶结合物稀释液、底物显色液、终止液、洗涤液,所述包被原为蛋白A或庆大霉素偶联抗原,所述酶结合物为酶标记的蛋白A抗体、酶标记的庆大霉素抗体,所述蛋白A抗体和庆大霉素抗体均是由免疫原免疫动物得到的,所述庆大霉素偶联抗原是由庆大霉素半抗原与卵清蛋白偶联得到,所述庆大霉素半抗原的制备方法为:
取庆大霉素1.39g,加纯水80ml溶解,取4,4′-二氟-3,3′-二硝基二苯砜0.344g加30ml甲醇溶解,加入到庆大霉素的水溶液中,加无水碳酸钾1.38g,室温搅拌3h,停止反应,加乙酸乙酯300ml萃取,静置,分去水相,有机相浓缩蒸干,无水乙醇20ml重结晶,得到氟硝基苯-庆大霉素半抗原产物0.34g,收率43.9%;
当包被原为蛋白A时,该试剂盒用于检测蛋白A;当包被原为庆大霉素偶联抗原时,该试剂盒用于检测庆大霉素。
2.如权利要求1所述的试剂盒,其特征在于所述庆大霉素半抗原的分子结构式为:
3.如权利要求1所述的试剂盒,其特征在于得到庆大霉素抗体的免疫原的制备方法如下:
取氟硝基苯-庆大霉素半抗原产物29mg,加DMF2ml溶解,得到半抗原溶液A液;取牛血清白蛋白(BSA)50mg,加0.05M PB缓冲液溶解,得到B液,将A液滴加到B液中,4℃反应12h,0.02M PBS透析纯化3天,每天换液三次,得到庆大霉素-BSA偶联物,即为免疫原,-20℃保存,备用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110118057.1A CN112904008B (zh) | 2021-02-04 | 2021-02-04 | 检测生物制品中蛋白a等杂质的酶联免疫试剂盒及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110118057.1A CN112904008B (zh) | 2021-02-04 | 2021-02-04 | 检测生物制品中蛋白a等杂质的酶联免疫试剂盒及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112904008A CN112904008A (zh) | 2021-06-04 |
CN112904008B true CN112904008B (zh) | 2024-08-13 |
Family
ID=76120690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110118057.1A Active CN112904008B (zh) | 2021-02-04 | 2021-02-04 | 检测生物制品中蛋白a等杂质的酶联免疫试剂盒及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112904008B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113960318A (zh) * | 2021-09-28 | 2022-01-21 | 苏州赛分科技股份有限公司 | 一种基于酶联免疫的重组蛋白a测定方法及试剂盒 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113030463A (zh) * | 2021-02-04 | 2021-06-25 | 北京勤邦生物技术有限公司 | 一种检测疫苗中蛋白a等杂质的试纸条及其应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1727900A (zh) * | 2005-06-20 | 2006-02-01 | 华南农业大学 | 庆大霉素免疫层析半定量试纸检测方法 |
CN101021535B (zh) * | 2007-03-12 | 2011-06-22 | 北京望尔康泰生物技术有限公司 | 检测庆大霉素药物的酶联免疫试剂盒及方法 |
CN101429242A (zh) * | 2008-12-04 | 2009-05-13 | 浙江大学 | 庆大霉素与载体蛋白偶联产物和庆大霉素抗体制备的方法及用途 |
US9234889B1 (en) * | 2008-12-18 | 2016-01-12 | Charm Sciences, Inc. | Method and test strip for detecting residues |
CN101907623B (zh) * | 2010-08-03 | 2013-05-08 | 中国农业大学 | 一种检测庆大霉素和/或小诺霉素的方法及其专用量子点荧光免疫试剂盒 |
CN104792996B (zh) * | 2014-01-20 | 2017-10-27 | 辽宁成大动物药业有限公司 | 一种狂犬病毒抗体(IgG)酶联免疫检测试剂盒及其检测方法 |
CN105004844B (zh) * | 2014-05-30 | 2016-06-22 | 北京勤邦生物技术有限公司 | 一种庆大霉素残留检测试纸条及其应用 |
CN105017347B (zh) * | 2014-05-30 | 2017-11-28 | 北京勤邦生物技术有限公司 | 庆大霉素半抗原及其制备方法和应用 |
CN104897895B (zh) * | 2015-04-14 | 2016-08-24 | 北京勤邦生物技术有限公司 | 一种庆大霉素的磁免疫化学发光检测试剂盒及其应用 |
CN111505294B (zh) * | 2020-04-03 | 2022-11-18 | 北京望尔生物技术有限公司 | 一种杂色曲霉素人工抗原在酶联免疫试剂盒中的应用 |
-
2021
- 2021-02-04 CN CN202110118057.1A patent/CN112904008B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113030463A (zh) * | 2021-02-04 | 2021-06-25 | 北京勤邦生物技术有限公司 | 一种检测疫苗中蛋白a等杂质的试纸条及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN112904008A (zh) | 2021-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2007257105B2 (en) | Elisa kit for detecting Sudan red and method thereof | |
CN101226194B (zh) | 无色孔雀石绿残留的酶联免疫检测试剂盒及其使用方法 | |
CN100445746C (zh) | 一种检测19-去甲睾酮的方法及其专用酶联免疫试剂盒 | |
CN101776685B (zh) | 检测三甲氧苄胺嘧啶药物的酶联免疫试剂盒及其应用 | |
CN109061169B (zh) | 一种检测啶虫脒的酶联免疫试剂盒及其应用 | |
CN110133306B (zh) | 检测西马特罗的酶联免疫试剂盒及其应用 | |
CN112904008B (zh) | 检测生物制品中蛋白a等杂质的酶联免疫试剂盒及其应用 | |
CN100582778C (zh) | 一种检测伊维菌素的方法及其专用酶联免疫试剂盒 | |
CN111848792B (zh) | 疫苗中牛血清白蛋白等杂质的抗体制备方法及检测方法 | |
CN109061171B (zh) | 一种检测氟节胺的酶联免疫试剂盒及其应用 | |
CN110684188A (zh) | 壬基酚聚氧乙烯醚半抗原和全抗原及其制备方法与应用 | |
CN113030463B (zh) | 一种检测疫苗中蛋白a等杂质的试纸条及其应用 | |
CN111812316B (zh) | 一种甲氰菊酯人工抗原在酶联免疫试剂盒中的应用 | |
CN111896737B (zh) | 一种蛇形菌素人工抗原在酶联免疫试剂盒中的应用 | |
CN111505294B (zh) | 一种杂色曲霉素人工抗原在酶联免疫试剂盒中的应用 | |
CN109541216B (zh) | 检测伊维菌素和阿维菌素的酶联免疫试剂盒及其应用 | |
CN109265395B (zh) | 一种二氯喹啉酸半抗原与抗原的制备方法及应用 | |
CN112098641B (zh) | 一种互隔交链孢霉素人工抗原在酶联免疫试剂盒中的应用 | |
CN111377888A (zh) | 一种闹羊花毒素iii半抗原及其制备方法与应用 | |
CN111273018B (zh) | 一种检测溴敌隆的酶联免疫试剂盒及其制备和应用 | |
CN109813922B (zh) | 检测氯丙那林的酶联免疫试剂盒及其应用 | |
CN111273041A (zh) | 一种检测鬼笔环肽的酶联免疫试剂盒及其制备和应用 | |
CN110618269A (zh) | 一种甲氨基阿维菌素单克隆抗体的制备及其应用 | |
CN110684110A (zh) | 一种甲基嘧啶磷单克隆抗体的制备及其应用 | |
CN109735502B (zh) | 一种分泌抗盐霉素单克隆抗体的杂交瘤细胞株及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |